OverviewSuggest Edit

NeuroMetrix is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company currently markets products for the detection, diagnosis, and monitoring of diabetic neuropathies such as diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome).
TypePublic
Founded1996
HQWoburn, MA, US
Websiteneurometrix.com
Employee Ratings3.3
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2019)23(-45%)
Revenue (FY, 2020)$7.4 M(-20%)
Share Price (Jul 2021)$20.8(+108%)
Cybersecurity ratingBMore

Key People/Management at Neurometrix

David E. Goodman

David E. Goodman

Director
Shai N. Gozani

Shai N. Gozani

Chairman of the Board, President, and Chief Executive Officer
Thomas T. Higgins

Thomas T. Higgins

Senior Vice President and Chief Financial Officer
Nancy E. Katz

Nancy E. Katz

Director
Michael J. MacDonald

Michael J. MacDonald

Senior Vice President and General Manager, Diagnostics
Xuan Kong

Xuan Kong

Chief Data Scientist
Show more

Neurometrix Office Locations

Neurometrix has an office in Woburn
Woburn, MA, US (HQ)
4 Gill St
Show all (1)

Neurometrix Financials and Metrics

Neurometrix Revenue

Embed Graph
View revenue for all periods
Neurometrix's revenue was reported to be $7.38 m in FY, 2020
USD

Revenue (FY, 2020)

7.4m

Gross profit (FY, 2020)

5.2m

Gross profit margin (FY, 2020), %

71.2%

Net income (FY, 2020)

(2.1m)

EBIT (FY, 2020)

(2.1m)

Market capitalization (21-Jul-2021)

79.1m

Closing stock price (21-Jul-2021)

20.8

Cash (31-Dec-2020)

5.2m

EV

74.9m
Neurometrix's current market capitalization is $79.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

10.4m7.6m5.3m5.5m7.3m12.0m17.1m16.1m9.3m7.4m

Cost of goods sold

4.7m3.6m2.2m2.6m4.0m7.1m10.2m8.7m7.0m2.1m

Gross profit

5.7m4.0m3.1m2.9m3.3m4.9m6.9m7.4m2.2m5.2m

Gross profit Margin, %

55%53%58%53%46%41%40%46%24%71%
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Neurometrix Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Neurometrix Online and Social Media Presence

Embed Graph

Neurometrix Company Culture

  • Overall Culture

    A+

    96/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Neurometrix News and Updates

NeuroMetrix stock more than triples on massive volume after fibromyalgia treatment gets FDA boost

Shares of NeuroMetrix Inc. rocketed 241% toward a two-year high on record volume, after the Massachusetts-based medical device company said its Quell transcutaneous electric nerve stimulator received "Breakthrough Designation" from the Food and Drug Administration to treat fibromyalgia symptoms in …

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology

WOBURN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® device has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treating the symptoms of fibromyalgia in adults.

NeuroMetrix, Inc. Announces Date for Second Quarter 2021 Financial Results Conference Call

WOBURN, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 second quarter financial results before the opening of the market on July 22, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on July 22, 2021 …

NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial

WOBURN, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to determine whether transcutaneous electrical nerve stimulation (TENS) is an effective, acceptable and feasib…

NeuroMetrix Announces That Top-Line Results from a Randomized Controlled Trial of Quell® for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

WOBURN, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that top-line results from a randomized controlled trial of Quell in patients with fibromyalgia will be presented at two upcoming pain medicine conferences.

NeuroMetrix Reports Q4 and Full Year 2020 Financial Results

WOBURN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company is focused on the development and global commercialization of non-invasive medical devices for the diagno…
Show more

Neurometrix Frequently Asked Questions

  • When was Neurometrix founded?

    Neurometrix was founded in 1996.

  • Who are Neurometrix key executives?

    Neurometrix's key executives are David E. Goodman, Shai N. Gozani and Thomas T. Higgins.

  • How many employees does Neurometrix have?

    Neurometrix has 23 employees.

  • What is Neurometrix revenue?

    Latest Neurometrix annual revenue is $7.4 m.

  • What is Neurometrix revenue per employee?

    Latest Neurometrix revenue per employee is $320.8 k.

  • Who are Neurometrix competitors?

    Competitors of Neurometrix include Yes Health, Biop Medical and Kaleido.

  • Where is Neurometrix headquarters?

    Neurometrix headquarters is located at 4 Gill St, Woburn.

  • Where are Neurometrix offices?

    Neurometrix has an office in Woburn.

  • How many offices does Neurometrix have?

    Neurometrix has 1 office.